B Cell Tetherin: A Flow Cytometric Cell ‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus

ObjectiveType I interferon (IFN) responses are broadly associated with autoimmune diseases, including systemic lupus erythematosus (SLE). Given the cardinal role of autoantibodies in SLE, this study was undertaken to investigate whether the findings of a B cell –specific IFN assay correlate with SLE activity.MethodsB cells and peripheral blood mononuclear cells (PBMCs) were stimulated with type I IFN and type II IFN. Gene expression was analyzed, and the expression of pathway ‐related membrane proteins was determined. A flow cytometry assay for tetherin (CD317), an IFN‐induced protein ubiquitously expressed on leukocytes, was validated in vitro and then clinically against SLE diagnosis, plasmablast expansion, and the British Isles Lupus Assessment Group (BILAG) 2004 score in a discovery cohort (n = 156 SLE patients, 30 rheumatoid arthritis [RA] patients, and 25 healthy controls). A second, longitudinal validation cohort of 80 SLE patients was also evaluated for flare prediction.ResultsIn vitro, a close cell ‐specific and dose‐response relationship between type I IFN–responsive genes and cell surface tetherin was observed in all immune cell subsets. Tetherin expression on multiple cell subsets was selectively responsive to stimulation with type I IFN compared to types II and III IFNs. In patient s amples from the discovery cohort, memory B cell tetherin showed the strongest associations with diagnosis (SLE:healthy control effect size 0.11 [P = 0.003]; SLE:R...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research

Related Links:

(GENEVA) — The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the anti-malarial drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date. In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its g...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 News Desk overnight wire Source Type: news
Authors: Ceribelli A, Selmi C Abstract Genomic predisposition fails to fully explain the onset of complex diseases, which is well illustrated by the largely incomplete concordance among monozygotic twins. Epigenetic mechanisms, including DNA methylation, chromatin remodeling, and non-coding RNA, are the link between environmental stimuli and disease onset on a permissive genetic background in autoimmune and chronic inflammatory diseases. Autoimmune diseases now include almost 100 conditions and are estimated to cumulatively affect up to 5% of the world population with a healthcare expenditure superior to cancer wor...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Pablo AH, Breaud AR, Clarke W Abstract Immunosuppressant medications help suppress the immune system response through inhibition of various checkpoints in the regulatory biochemical pathway. This is useful in prevention of organ rejection in transplantation or in the treatment of autoimmune diseases such as lupus or rheumatoid arthritis. Quantification of immunosuppressive drugs in blood is needed clinically for optimization of treatment and to avoid toxicity or unwanted side effects. Here, we describe a quantitative method to determine the concentration of cyclosprine A, tacrolimus, sirolimus, and everoli...
Source: Current Protocols in Toxicology - Category: Toxicology Tags: Curr Protoc Toxicol Source Type: research
In the largest observational study thus far investigating the drug hydroxychloroquine as a treatment for COVID-19, researchers found little evidence that it helps, and worrying evidence that the medication may cause harm. In a study published May 22 in the journal Lancet, scientists in the U.S. and Switzerland report on an analysis of more than 96,000 people hospitalized with confirmed COVID-19 in 671 hospitals on six continents. Nearly 15,000 patients were treated with one of the following: chloroquine (which is an older version of hydroxychloroquine), hydroxychloroquine, or either of those drugs in combination with an an...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
This study characterized trends in utilization of CABG in patients with CTD and the impact of the disease on mortality, in-hospital complications, length of stay (LOS) and costs. METHODS: The 2005-2015 National Inpatient Sample was used to identify all adult patients undergoing isolated CABG. The CTD cohort included rheumatoid arthritis, lupus erythematosus, antiphospholipid syndrome (APLS), among others. Hierarchical multivariable logistic models were used to calculate the independent impact of CTD on clinical outcomes and costs. RESULTS: Of an estimated 2,101,591 million patients, 41,567 (1.8%) were diagnosed w...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
AbstractHydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020. Interestingly, some reports indicate that this wonder drug may be also beneficial ...
Source: Journal of NeuroImmune Pharmacology - Category: Drugs & Pharmacology Source Type: research
(Federation of American Societies for Experimental Biology) In its May issue, The FASEB Journal is publishing a comprehensive review on the science and clinical experiences with the drugs chloroquine and hydroxychloroquine, first introduced as effective weapons against malaria, rheumatoid arthritis, and the autoimmune disease lupus. Recent anecdotal reports suggested these drugs might be effective against the SARS-CoV-2 virus, the cause of the COVID-19 pandemic. This new review describes the growing skepticism regarding adoption of chloroquine and hydroxychloroquine for the respiratory infection caused by this virus.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Prescriptions for two antimalarial drugs jumped by 46 times the average when the president promoted them on TV. There ’s no proof they work against Covid-19.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Hydroxychloroquine (Drug) Azithromycin (Drug) Coronavirus (2019-nCoV) United States Politics and Government Autoimmune Diseases Lupus Erythematosus Rheumatoid Arthritis Trump, Donald J Food and Drug Administration Source Type: news
by Keisha Ray, Ph.D. I take the drug hydroxychloroquine, brand name Plaquenil, for an autoimmune disease. Hydroxychloroquine was once used to treat malaria and is now commonly used to treat a range of inflammatory disorders like lupus and rheumatoid arthritis. If this drug sounds familiar it is likely because it has frequently been in the news as a potential therapy for COVID19. During multiple press conferences the president has touted this drug as a potential cure for COVID19. Medical professionals like Dr.…
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Ethics Featured Posts Health Care Health Policy & Insurance Human Subjects Research & IRBs Informed Consent Pharmaceuticals Politics Public Health #covid19 #diaryofaplagueyear COVID-19 Source Type: blogs
szka Corticotropin (ACTH, previously an adrenocorticotropic hormone) is used in the diagnosis and treatment of pituitary gland disorders, adrenal cortex disorders, and other diseases, including autoimmune polymyositis, systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. So far, the ointment dosage form containing ACTH for use on the skin is unknown. Therefore, it seems appropriate to develop a semi-solid formulation with corticotropin. Emulsion ointments were prepared using an Unguator based on the cream base Lekobaza® containing corticotropin in different conc...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
More News: Arthritis | Autoimmune Disease | Genetics | Lupus | Rheumatoid Arthritis | Rheumatology | Rituxan | Study | UK Health